Skip to main content

Advertisement

SpringerLink
Log in

Phase II study of a gemcitabine and cisplatin combination regimen in taxane resistant metastatic breast cancer

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose: To determine the safety and efficacy of gemcitabine and cisplatin in patients with taxane resistant metastatic breast cancer. Patients and methods: Thirty-three taxane resistant metastatic breast cancer patients were treated with gemcitabine 1,250 mg/m2 IV infusion over 30 min on days 1 and 8, and with cisplatin 75 mg/m2 by IV infusion over 1 h on day 1 in 21 day cycles. Results: Of the 30 evaluable patients, there were 9 (30%) partial responses and no complete response, an overall objective response rate of 30%. Median time to progression and median survival duration for all study subjects were 7 (95% CI 5.1–8.9 months) and 15 months (95% CI 10.5–19.5 months), respectively. Toxicities included grade 3 and 4 leucopenia in 10 (30%), thrombocytopenia in 6 (18%), anemia in 2 (6%) and oral mucositis in 2 (6%). No grade 3 or 4 peripheral neuropathy, renal dysfunction, hepatic dysfunction, or nausea/vomiting was observed, and no treatment-related deaths occurred. Conclusion: The described gemcitabine plus cisplatin combination was found to be an active and tolerable salvage regimen in patients with taxane resistant metastatic breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU (1996) Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14:2197–2205

    PubMed  CAS  Google Scholar 

  2. Merriman RL, Hertel LW, Schultz RM, Houghton PJ, Houghton JA, Rutherford PG, et al (1996) Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models. Invest New Drugs 14:243–247

    Article  PubMed  CAS  Google Scholar 

  3. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA (1994) Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 12:1535–1540

    PubMed  CAS  Google Scholar 

  4. Gatzemeier U, Shepherd FA, Le Chevalier T, Weynants P, Cottier B, Groen HJ, et al (1996) Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur J Cancer 32:243–248

    Article  Google Scholar 

  5. Seidman AD (2001) The evolving role of gemcitabine in the management of breast cancer. Oncology 60:189–198

    Article  PubMed  CAS  Google Scholar 

  6. Kolaric K, Roth A (1983) Phase II clinical trial of cis-dichlorodiammine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer. Cancer Chemother Pharmacol 11:108–112

    PubMed  CAS  Google Scholar 

  7. Mechl Z, Sopkova B (1984) CAP (cyclophosphamide, adriamycin, cisplatin in the treatment of advanced breast cancer. Neoplasma 31:431–435

    PubMed  CAS  Google Scholar 

  8. Sledge GW Jr, Loehrer PJ Sr, Roth BJ, Einhorn LH (1988) Cisplatin as first-line therapy for metastatic breast cancer. J Clin Oncol 6:1811–1814

    PubMed  Google Scholar 

  9. Bajorin D, Bosl GJ, Fein R (1987) Phase I trial of escalating doses of cisplatin in hypertonic saline. J Clin Oncol 5:1589–1593

    PubMed  CAS  Google Scholar 

  10. Forastiere AA, Hakes TB, Wittes JT, Wittes RE (1982) Cisplatin in the treatment of metastatic breast carcinoma: A prospective randomized trial of two dosage schedules. Am J Clin Oncol 5:243–247

    PubMed  CAS  Google Scholar 

  11. Martino S, Samal BA, Singhakowinta A, Yoshida S, Mackenzie M, Jain J et al (1984) A phase II study of cis-diamminedichloroplatinum II for advanced breast cancer. Two dose schedules. J Cancer Res Clin Oncol 108:354–356

    Article  PubMed  CAS  Google Scholar 

  12. Ostrow S, Egorin M, Aisner J, Bachur N, Wiernik PH (1980) High-dose cis-diamminedichloro-platinum therapy in patients with advanced breast cancer: pharmacokinetics, toxicity, and therapeutic efficacy. Cancer Clin Trials 3:23–27

    PubMed  CAS  Google Scholar 

  13. Ramnath N, LoRusso P, Simon M, Martino S (1997) Phase II evaluation of cisplatin and WR2721 for refractory metastatic breast cancer. Am J Clin Oncol 20:368–372

    Article  PubMed  CAS  Google Scholar 

  14. Yap HY, Salem P, Hortobagyi GN, Bodey GP Sr, Buzdar AU, Tashima CK et al (1978) Phase II study of cis-dichlorodiammineplatinum(II) in advanced breast cancer. Cancer Treat Rep 62:405–408

    PubMed  CAS  Google Scholar 

  15. Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Peters GJ (1994) Synergistic interaction between cisplatin and gemcitabine in ovarian and colon cancer cell lines. Adv Exp Med Biol 370:139–143

    PubMed  CAS  Google Scholar 

  16. Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Peters GJ (1996) Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 2:521–530

    PubMed  CAS  Google Scholar 

  17. Peters GJ, Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Braakhuis BJ (1995) Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22:72–79

    PubMed  CAS  Google Scholar 

  18. Nagourney RA, Link JS, Blitzer JB, Forsthoff C, Evans SS (2000) Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients. J Clin Oncol 18:2245–2249

    PubMed  CAS  Google Scholar 

  19. Heinemann V, Stemmler HJ, Wohlrab A, Bosse D, Losem C, Kahlert S, et al (2005) High efficacy of gemcitabine and cisplatin in patients with predominantly anthracycline- and taxane-pretreated metastatic breast cancer. Cancer chemother Pharmacol 15:1–7

    Google Scholar 

  20. Mohran TZ (2004) Gemcitabine and Cisplatin combination chemotherapy as a first-line treatment in patients with metastatic breast cancer. J Egypt Natl Canc Inst 16:8–14

    PubMed  Google Scholar 

  21. Verma S, Trudeau M, Dranitsaris G, Clemons M, Joy AA, MacKey JR (2005) What is the best chemotherapy treatment option for anthracycline and taxane pretreated metastatic breast cancer? J Clin Oncol 23:6260

    Article  PubMed  Google Scholar 

  22. Keller AM, Mennel RG, Georgoulias VA, Nabholtz JM, Erazo A, Lluch A, et al (2004) Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol 22:3893–3901

    Article  PubMed  CAS  Google Scholar 

  23. Frasci G, D’Aiuto G, Comella P, Thomas R, Capasso I, Botti G, et al (2001) Gemcitabine/cyclophosphamide/5-fluorouracil/folinic acid triplet combination in anthracycline- and taxane-refractory breast cancer patients: a southern Italy cooperative oncology group phase I/II study. Semin Oncol 28:50–56

    Article  PubMed  CAS  Google Scholar 

  24. Schmid P, Heilmann V, Schulz CO, Dieing A, Lehenbauer-Dehm S, Jehn C et al (2005) Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: a phase II study. J Cancer Res Clin Oncol 131:568–574

    Article  PubMed  CAS  Google Scholar 

  25. Smorenburg CH, Bontenbal M, Seynaeve C, van Zuylen C, de Heus G, Verweij J et al (2001) Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane. Breast Cancer Res Treat 66:83–87

    Article  PubMed  CAS  Google Scholar 

  26. Singal PK, Iliskovic N (1998) Doxorubicin-induced cardiomyopathy. N Engl J Med 339:900–905

    Article  PubMed  CAS  Google Scholar 

  27. Sandler AB, Nemunaitis J, Denham C, von Pawel J, Cormier Y, Gatzemeier U, et al (2000) Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 18:122–130

    PubMed  CAS  Google Scholar 

  28. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068–3077

    PubMed  Google Scholar 

Download references

Acknowledgment

This work was supported in part by the Brain Korea 21 Project and was supported by the Korean Health 21 R and D Project, Ministry of Health and Welfare, Republic of Korea (Grant no. 01-PG3-PG6-01GN07-0004).

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Division of Hematology/Oncology, College of Medicine, Korea University Guro Hospital, 97 Gurodong-gil, Guro-ku, Seoul, Korea, 152-703

    Jae Hong Seo, Sang Cheul Oh, Cheul Won Choi, Byung Soo Kim, Sang Won Shin, Yeul Hong Kim & Jun Suk Kim

  2. Department of Pathology, College of Medicine, Korea University, Seoul, Korea

    Ae-Ree Kim

  3. Department of Surgery, College of Medicine, Korea University, Seoul, Korea

    Jae-Bok Lee & Bum Hwan Koo

Authors
  1. Jae Hong Seo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sang Cheul Oh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cheul Won Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Byung Soo Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sang Won Shin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yeul Hong Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jun Suk Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ae-Ree Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jae-Bok Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Bum Hwan Koo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jun Suk Kim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Seo, J.H., Oh, S.C., Choi, C.W. et al. Phase II study of a gemcitabine and cisplatin combination regimen in taxane resistant metastatic breast cancer. Cancer Chemother Pharmacol 59, 269–274 (2007). https://doi.org/10.1007/s00280-006-0266-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-006-0266-x

Keywords

Search

Navigation